Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Sep 3;2015(9):CD001726.
doi: 10.1002/14651858.CD001726.pub5.

Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis

Lorne A Becker  1 , Jeffrey Hom, Miguel Villasis-Keever, Johannes C van der Wouden
Affiliations
Meta-Analysis

Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis

Lorne A Becker et al. Cochrane Database Syst Rev. .

Abstract

Background: The diagnosis of acute bronchitis is made on clinical grounds and a variety of clinical definitions have been used. There are no clearly effective treatments for the cough of acute bronchitis. Beta2-agonists are often prescribed, perhaps because clinicians suspect many patients also have reversible airflow restriction (as seen in asthma or chronic obstructive pulmonary disease (COPD)) contributing to the symptoms.

Objectives: To determine whether beta2-agonists improve acute bronchitis symptoms in people with no underlying pulmonary disease (such as asthma, COPD or pulmonary fibrosis).

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 5, MEDLINE (January 1966 to May 2015), EMBASE (1974 to May 2015), Web of Science (2011 to May 2015) and LILACS (1982 to May 2015).

Selection criteria: Randomised controlled trials (RCTs) which allocated people (adults, or children over two years of age) with acute bronchitis or acute cough and without known pulmonary disease to beta2-agonist versus placebo, no treatment or alternative treatment.

Data collection and analysis: Three review authors independently selected outcomes and extracted data while blinded to study results. Two review authors independently assessed each trial for risk of bias. We analysed trials in children and adults separately.

Main results: Two trials of moderate quality in children (n = 134) with no evidence of airflow restriction did not find any benefits from oral beta2-agonists. Five trials in adults (n = 418) had mixed results but overall summary statistics did not reveal any significant benefits from oral (three trials) nor from inhaled (two trials) beta2-agonists. Three studies with low-quality evidence demonstrated no significant differences in daily cough scores, nor in the percentage of adults still coughing after seven days (control group 71%; risk ratio (RR) 0.86, 95% confidence interval (CI) 0.63 to 1.18; 220 participants). In one trial, subgroups with evidence of airflow limitation had lower symptom scores if given beta2-agonists. The trials that noted quicker resolution of cough with beta2-agonists were those with a higher proportion of people wheezing at baseline. Low-quality evidence suggests that adults given beta2-agonists were more likely to report tremor, shakiness or nervousness (RR 7.94, 95% CI 1.17 to 53.94; 211 participants; number needed to treat for an additional harmful outcome (NNTH) 2).

Authors' conclusions: There is no evidence to support the use of beta2-agonists in children with acute cough who do not have evidence of airflow restriction. There is also little evidence that the routine use of beta2-agonists is helpful for adults with acute cough. These agents may reduce symptoms, including cough, in people with evidence of airflow restriction. However, this potential benefit is not well supported by the available data and must be weighed against the adverse effects associated with their use.

PubMed Disclaimer

Conflict of interest statement

Lorne Becker: none known. Jeffrey Hom: none known. Miguel Villasis‐Keever: none known. Johannes van der Wouden: none known.

Figures

1
1
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 1 Cough after seven days.
1.2
1.2. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 2 Mean cough score after one day.
1.3
1.3. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 3 Mean cough score after two days.
1.4
1.4. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 4 Mean cough score after three days.
1.5
1.5. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 5 Mean cough score after four days.
1.6
1.6. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 6 Mean cough score after five days.
1.7
1.7. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 7 Mean cough score after six days.
1.8
1.8. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 8 Mean cough score after seven days.
1.9
1.9. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 9 Shaking or tremor.
1.10
1.10. Analysis
Comparison 1 Beta2‐agonists versus placebo in children, Outcome 10 Other side effects.
2.1
2.1. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 1 Cough after seven days.
2.2
2.2. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 2 Productive cough after seven days.
2.3
2.3. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 3 Night cough after seven days.
2.4
2.4. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 4 Mean cough score after one day.
2.5
2.5. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 5 Mean cough score after two days.
2.6
2.6. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 6 Mean cough score after three days.
2.7
2.7. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 7 Mean cough score after four days.
2.8
2.8. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 8 Mean cough score after five days.
2.9
2.9. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 9 Mean cough score after six days.
2.10
2.10. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 10 Mean cough score after seven days.
2.11
2.11. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 11 Not working by day seven.
2.12
2.12. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 12 Shaking, tremor or nervousness.
2.13
2.13. Analysis
Comparison 2 Beta2‐agonists versus placebo in adults, Outcome 13 Other side effects.
3.1
3.1. Analysis
Comparison 3 Beta2‐agonists versus erythromycin in adults, Outcome 1 Cough after seven days.
3.2
3.2. Analysis
Comparison 3 Beta2‐agonists versus erythromycin in adults, Outcome 2 Productive cough after seven days.
3.3
3.3. Analysis
Comparison 3 Beta2‐agonists versus erythromycin in adults, Outcome 3 Night cough after seven days.
See this image and copyright information in PMC

Update of

Comment in

References

References to studies included in this review

Bernard 1999 {published and unpublished data}
    1. Bernard DW, Goepp JG, Duggan AK, Serwint JR, Rowe PC. Is oral albuterol effective for acute cough in non‐asthmatic children?. Acta Pediatrica 1999;88(4):465‐7. - PubMed
Hueston 1991 {published data only}
    1. Hueston W. A comparison of albuterol and erythromycin for the treatment of acute bronchitis. Journal of Family Practice 1991;33(5):476‐80. - PubMed
Hueston 1994 {published data only}
    1. Hueston W. Albuterol delivered by metered‐dose inhaler to treat acute bronchitis: a placebo‐controlled double‐blind study. Journal of Family Practice 1994;39(5):437‐40. - PubMed
Korppi 1991 {published data only}
    1. Korppi M, Laurikainen K, Pietikäinen M, Silvasti M. Antitussives in the treatment of acute transient cough in children. Acta Pediatrica Scandinavia 1991;80(10):969‐71. - PubMed
Littenberg 1996 {published and unpublished data}
    1. Littenberg B, Wheeler M, Smith DS. A randomized controlled trial of oral albuterol in acute cough. Journal of Family Practice 1996;42(1):49‐53. - PubMed
Melbye 1991 {published and unpublished data}
    1. Melbye H, Aasebø U, Straume B. Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo‐controlled double‐blind study. Family Practice 1991;8(3):216‐22. - PubMed
Tukiainen 1986 {published data only}
    1. Tukiainen H, Karttunen P, Silvasti M, Flygare U, Korhonen R, Korhonen T, et al. The treatment of acute transient cough: a placebo‐controlled comparison of dextromethorphan and dextromethorphan‐beta2‐sympathomimetic combination. European Journal of Respiratory Diseases 1986;69(2):95‐9. - PubMed

References to studies excluded from this review

Chang 1998 {published data only}
    1. Chang AB, Phelan PD, Carlin JB, Sawyer SM, Robertson CF. A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough. Archives of Diseases of Children 1998;79(1):6‐11. - PMC - PubMed
Ovchinnikov 2014 {published data only}
    1. Ovchinnikov AI, Paniakina MA, Korostelev SA, Mitiuk AM. Therapeutic modalities for the management of cough associated with acute respiratory viral infection, effective in an otolaryngologist's practice. Vestnik Otorinolaringologii 2014;2014(2):86‐9. [PUBMED: 24781181] - PubMed
Zanasi 2014 {published data only}
    1. Zanasi A, Lecchi M, Forno M, Fabbri E, Mastroroberto M, Mazzolini M, et al. A randomized, placebo‐controlled, double‐blind trial on the management of post‐infective cough by inhaled ipratropium and salbutamol administered in combination. Pulmonary Pharmacology & Therapeutics 2014;29(2):224‐32. [PUBMED: 25111667] - PubMed

Additional references

Armstrong 1999
    1. Armstrong GL, Pinner RW. Outpatient visits for infectious diseases in the United States, 1980 through 1996. Archives of Internal Medicine 1999;159(21):2531‐6. - PubMed
Dunlay 1984
    1. Dunlay J, Reinhardt R. Clinical features and treatment of acute bronchitis. Journal of Family Practice 1984;18(5):719‐22. - PubMed
Ellul‐Micallef 1983
    1. Ellul‐Micallef R. Effect of terbutaline sulphate in chronic "allergic" cough. British Medical Journal (Clinical Research Ed) 1983;287(6397):940‐3. - PMC - PubMed
Gadomski 2014
    1. Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD001266.pub4; PUBMED: 24937099] - DOI - PMC - PubMed
Gonzales 1997
    1. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278(11):901‐4. - PubMed
Gwaltney 1995
    1. Gwaltney JM. Acute bronchitis. In: Mandell GL, Bennett JE, Dolin R editor(s). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 4th Edition. New York: Churchill Livingstone, 1995:606‐8.
Hahn 1991
    1. Hahn D, Dodge R, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult‐onset asthma. JAMA 1991;266(2):225‐30. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbooks.org.
Holleman 1995
    1. Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation?. JAMA 1995;273(4):313‐9. - PubMed
ICHPPC‐2 1983
    1. ICHPPC. ICHPPC‐2‐Defined (International Classification of Health Problems in Primary Care). 3rd Edition. Oxford: Oxford University Press, 1983.
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. - PubMed
Johnson 1991
    1. Johnson D, Osborn LM. Cough variant asthma: a review of the clinical literature. Journal of Asthma 1991;28(2):85‐90. - PubMed
Karlsson 1999
    1. Karlsson JA, Fuller RW. Pharmacological regulation of the cough reflex ‐ from experimental models to antitussive effects in man. Pulmonary Pharmacology & Therapeutics 1999;12(4):215‐28. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbooks.org.
Lui 1996
    1. Lui PW, Hsing CH, Chu YC. Terbutaline inhalation suppresses fentanyl‐induced coughing. Canadian Journal of Anaesthesia 1996;43(12):1216‐9. - PubMed
Mainous 1996
    1. Mainous AG 3rd, Zoorob RJ, Hueston WJ. Current management of acute bronchitis in ambulatory care: the use of antibiotics and bronchodilators. Archives of Family Medicine 1996;5(2):79‐83. - PubMed
Marrie 1998
    1. Marrie TJ. Acute bronchitis and community‐acquired pneumonia. In: Fishman AP, Elias JA editor(s). Fishman's Pulmonary Diseases and Disorders. 3rd Edition. New York: McGraw‐Hill, 1998:1985.
Melbye 1994
    1. Melbye H, Kongerud J, Vorland L. Reversible airflow limitation in adults with respiratory infection. European Respiratory Journal 1994;7(7):1239‐45. - PubMed
Meza 1994
    1. Meza RA, Bridges‐Webb C, Sayer GP, Miles DA, Traynor V, Neary S. The management of acute bronchitis in general practice: results from the Australian Morbidity and Treatment Survey. Australian Family Physician 1994;23(8):1550‐3. - PubMed
Oeffinger 1997
    1. Oeffinger KC, Snell LM, Foster BM, Panico KG, Archer RK. Diagnosis of acute bronchitis in adults: a national survey of family physicians. Journal of Family Practice 1997;45(5):402‐9. - PubMed
Oeffinger 1998
    1. Oeffinger KC, Snell LM, Foster BM, Panico KG, Archer RK. Treatment of acute bronchitis in adults: a national survey of family physicians. Journal of Family Practice 1998;46:469‐75. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Smith 2014
    1. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD000245.pub3; PUBMED: 24585130] - DOI - PubMed
Stern 1996
    1. Stern RC. Bronchitis. In: Berhman RE, Kliegman RM, Arvin AM, Nelson WE editor(s). Nelson Textbook of Pediatrics. 15th Edition. Philadelphia: W.B. Saunders, 1996:1210.
Verheij 1990
    1. Verheij TJM, Hermans J, Kapstein AA, Wijkel D, Mulder JD. Acute bronchitis: general practitioners' views regarding diagnosis and treatment. Family Practice 1990;7(3):175‐80. - PubMed
Vesco 1988
    1. Vesco D, Kleisbauer JP, Orehek J. Attenuation of bronchofibroscopy‐induced cough by an inhaled beta2‐adrenergic agonist, fenoterol. American Reviews of Respiratory Diseases 1988;138(4):805‐6. - PubMed
Vinson 1991
    1. Vinson DC. Acute bronchitis in children: building a clinical definition. Family Practice Research Journal 1991;11(1):75‐81. - PubMed
Weller 1996
    1. Weller KA. Bronchitis. In: Rakel RE editor(s). Saunders Manual of Medical Practice. Philadelphia: W. B. Saunders, 1996:120‐1.
Williamson 1987
    1. Williamson H. Pulmonary function tests in acute bronchitis: evidence for reversible airway obstruction. Journal of Family Practice 1987;25(3):251‐6. - PubMed

References to other published versions of this review

Becker 2011
    1. Becker LA, Hom J, Villasis‐Keever M, Wouden JC. Beta2‐agonists for acute bronchitis. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD001726.pub4] - DOI - PubMed
Smucny 1999
    1. Smucny J, Becker L, Glazier R, McIsaac W. Beta‐agonists for Acute Bronchitis. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001726] - DOI - PubMed
Smucny 2001
    1. Smucny J, Flynn C, Becker L, Glazier R. Beta2‐agonists for acute bronchitis. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001726] - DOI - PubMed
Smucny 2004
    1. Smucny J, Flynn C, Becker L, Glazier R. Beta2‐agonists for acute bronchitis. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD001726.pub2] - DOI - PubMed
Smucny 2006
    1. Smucny J, Becker L, Glazier R. Beta2‐agonists for acute bronchitis. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD001726.pub3] - DOI - PubMed
Smucny 2009
    1. Smucny J, Becker L, Glazier R, McIsaac W. Beta‐agonists for Acute Bronchitis. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001726] - DOI - PubMed

Publication types

Substances